Get the Stockscreener App
4.60
5.35%
-0.26
After Hours:
4.61
0.01
+0.22%
Cel-Sci Corp. stock is traded at $4.60, with a volume of 40,890.
It is down -5.35% in the last 24 hours and down -10.33% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$4.86
Open:
$4.85
24h Volume:
40,890
Relative Volume:
0.60
Market Cap:
$38.68M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-9.0196
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
-6.12%
1M Performance:
-10.33%
6M Performance:
-39.71%
1Y Performance:
-63.11%
1-Day Range:
$4.60
$5.14
1-Week Range:
$4.60
$5.49
52-Week Range:
$1.98
$20.41
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
4.60 | 40.87M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
Investment Review: Is CEL SCI Corporation trading at a discountJuly 2025 Snapshot & Comprehensive Market Scan Reports - baoquankhu1.vn
IPO Launch: Is CEL SCI Corporation trading at a discountWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.9% – Should You Sell? - Defense World
Why did CVM shares rally over 7% today? - MSN
Why DID CVM Shares Rally Over 7% Today? - Asianet Newsable
Kersten Geert buys Cel Sci (CVM) shares worth $200000 By Investing.com - Investing.com Australia
Insider Buying: Geert Kersten Acquires Additional Shares of CEL-SCI Corp (CVM) - GuruFocus
Kersten Geert buys Cel Sci (CVM) shares worth $200000 - Investing.com
Profit Recap: Does CEL SCI Corporation stock have upside surprise potentialWeekly Investment Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Cel Sci (CVM) Options Delisting Set for January 20th - GuruFocus
Surprises Report: Why CEL SCI Corporation stock could outperform in 2025M&A Rumor & AI Enhanced Trading Alerts - Bộ Nội Vụ
Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.5% – What’s Next? - Defense World
Cel-Sci Corporation (CVM) Investor Outlook: Exploring A Potential 625% Upside - DirectorsTalk Interviews
Is CEL SCI Corporation stock dividend yield sustainable2025 Geopolitical Influence & Long-Term Safe Investment Ideas - Улправда
Is CEL SCI Corporation stock positioned well for digital economyJuly 2025 Selloffs & Expert Curated Trade Setup Alerts - Улправда
Is CEL SCI Corporation stock a contrarian buyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Cel-sci-sci Corp : Dutton Associates Announces Investment Opinion - marketscreener.com
CEL-SCI (CVM) Chief Scientific Officer reports purchase of 456 shares - Stock Titan
CEL-SCI (CVM) CFO Patricia Prichep reports insider stock purchase - Stock Titan
CEL-SCI Corp (CVM) CEO and Director reports purchase of 998 shares - Stock Titan
Cel-Sci Corporation (CVM) Stock Analysis: Exploring a Potential 707% Upside with Innovative Cancer Therapies - DirectorsTalk Interviews
Cel-Sci (CVM) Reduces R&D Costs and Narrows Net Loss in FY 2025 - GuruFocus
Cancer drug Multikine nears final U.S. trial, seeks Saudi breakthrough status - Stock Titan
CEL SCI CORP SEC 10-K Report - TradingView — Track All Markets
CEL-SCI (NYSE American: CVM) details Multikine survival data and cash outlook - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Why CEL SCI Corporation stock is rated strong buyWeekly Risk Report & Safe Swing Trade Setups - Улправда
CEL SCI Corp CEO Acquires 8,389 Shares - TradingView — Track All Markets
CEL-SCI Corp (CVM) CEO Geert Kersten reports insider purchase of 8,389 shares - Stock Titan
Can Cel Sci Corporation stock deliver double digit returns2025 Earnings Impact & Safe Capital Allocation Plans - Newser
Will CEL SCI Corporation (LSR) stock gain from lower interest ratesJuly 2025 Analyst Calls & Free Daily Entry Point Trade Alerts - Newser
Will CEL SCI Corporation (LSR) stock attract long term capital inflowsJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - Newser
Is CEL SCI Corporation (LSR) stock resilient in recession scenarios2025 Top Decliners & Community Verified Trade Alerts - Newser
Why CEL SCI Corporation (LSR) stock is upgraded to buy2025 Short Interest & Daily Volume Surge Trade Alerts - Newser
How reliable is Cel Sci Corporation stock dividend growthJuly 2025 Movers & Smart Swing Trading Techniques - Newser
Why Cel Sci Corporation stock is upgraded to buyJuly 2025 Intraday Action & AI Enhanced Execution Alerts - Newser
CEL-SCI (CVM) Stock Analysis Report | Financials & Insights - Benzinga
How CEL SCI Corporation (LSR) stock trades under stagflationJuly 2025 Opening Moves & Technical Pattern Alert System - Newser
Why Cel Sci Corporation stock stays undervaluedEarnings Trend Report & Daily Technical Forecast Reports - Newser
Cel-Sci revises shareholder rights agreement following board approval By Investing.com - Investing.com South Africa
Cel-Sci revises shareholder rights agreement following board approval - Investing.com
CVM Board revises CEL-SCI shareholder rights agreement, files Exhibit 4 - Stock Titan
Why CEL SCI Corporation stock could see breakout soonShort Setup & Real-Time Volume Analysis Alerts - newser.com
Will Cel Sci Corporation stock profit from AI boomQuarterly Investment Review & Fast Moving Trade Plans - newser.com
Is Cel Sci Corporation stock a buy during volatile marketsInflation Watch & Fast Exit and Entry Strategy Plans - newser.com
Why analysts recommend CEL SCI Corporation (LSR) stockJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
Is CEL SCI Corporation stock attractive for hedge fundsTake Profit & Risk Adjusted Buy and Sell Alerts - newser.com
Is Cel Sci Corporation stock protected from inflation2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
What recovery options are there for CEL SCI CorporationTrade Volume Summary & Growth Focused Stock Reports - newser.com
Will CEL SCI Corporation stock benefit from upcoming earnings reports2025 Top Gainers & Verified Short-Term Trading Plans - newser.com
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):